BIOME AUSTRALIA LIMITED (BIO)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

BIO - BIOME AUSTRALIA LIMITED

FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Household & Personal Products
Debt/EBITDA: -0.78
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.515

20 Dec
2024

-0.050

OPEN

$0.57

-8.85%

HIGH

$0.57

319,016

LOW

$0.52

TARGET
$0.85 65.0% upside
OTHER COMPANIES IN THE SAME SECTOR
1AD . ACR . ACW . ADO . AFP . AGH . AGN . ARX . AVH . BOT . CSL . CUV . DXB . EOF . GSS . HXL . IDT . IMM . IMU . IVX . LGP . MAP . MDC . MSB . MVP . MYX . NEU . NUZ . NXS . OCC . OPT . OSL . PAR . PER . PNV . PYC . RAC . RCE . SPL . TLX . TRP . VIT . ZNO .
FNARENA'S MARKET CONSENSUS FORECASTS
BIO: 1
Title FY23
Actual		 FY24
Actual		 FY25
Forecast		 FY26
Forecast
EPS (cps) xxx - 0.8 0.4 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A 128.8 xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2024 FactSet UK Limited. All rights reserved
Title 20202021202220232024
EPS Basic xxxxxxxxxxxx-0.8
DPS All xxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxx13.0 M
Book Value Per Share xxxxxxxxxxxx1.4
Net Operating Cash Flow xxxxxxxxxxxx-0.2 M
Net Profit Margin xxxxxxxxxxxx-12.84 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 20202021202220232024
Return on Capital Employed xxxxxxxxxxxx-51.47 %
Return on Invested Capital xxxxxxxxxxxx-44.08 %
Return on Assets xxxxxxxxxxxx-21.09 %
Return on Equity xxxxxxxxxxxx-51.47 %
Return on Total Capital xxxxxxxxxxxx-42.84 %
Free Cash Flow ex dividends xxxxxxxxxxxx-0.2 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 20202021202220232024
Short-Term Debt xxxxxxxxxxxx1 M
Long Term Debt xxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxx1 M
Goodwill - Gross xxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxx3 M
Price To Book Value xxxxxxxxxxxx42.96

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 20202021202220232024
Capex xxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxx0.17 %
Cost of Goods Sold xxxxxxxxxxxx5 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxx10 M
Research & Development xxxxxxxxxxxx-
Investments - Total xxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

25/10/2024

1

Buy

$0.85

65.05%

Biome Australia keeps notching up records, Bell Potter observes, with 1Q25 cash receipts at around $3.89m and sales circa $4.25m, both new highs.

Sales growth advanced 68% year-on-year because of same-stores pharmacy sales. FY25 total sales are tracking to around $17m annualising the quarter, compared to the broker's estimate of around $18.9m. A guidance update is possible on Nov 19 at the AGM.

A one-off circa $1.5m staff bonuses underpinned the first negative operating cash flow quarter in the last four quarters.

There are no changes to the analyst's forecasts. Unchanged Buy rating and 85c target.

FORECAST
Bell Potter forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.40 cents.
Bell Potter forecasts a full year FY26 dividend of 0.00 cents and EPS of 1.70 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

BIO STOCK CHART

FNArena News on BIO

1
Rudi’s View: Banks, WiseTech, Redox & Integral Diagnostics

Dec 19 2024 - Rudi's View
2
FNArena Corporate Results Monitor – 27-08-2024

Aug 27 2024 - Australia
3
Australian Broker Call *Extra* Edition – Nov 01, 2022

Nov 01 2022 - Daily Market Reports
4
Australian Broker Call *Extra* Edition – Sep 06, 2022

Sep 06 2022 - Daily Market Reports
5
Australian Broker Call *Extra* Edition – Aug 04, 2022

Aug 04 2022 - Daily Market Reports

Latest Pharmaceuticals & Biotech/Lifesciences News

1
Dr Boreham’s Crucible: Arovella Therapeutics

Aug 29 2024 - Small Caps
2
ResMed’s Margin Upside Excites

Aug 07 2024 - Australia
3
Dr Boreham’s Crucible: Aroa Biosurgery

Jul 29 2024 - Small Caps
4
CSL Shares Breaking Free

Jul 23 2024 - Technicals
5
Dr Boreham’s Crucible: SDI

Jul 19 2024 - Small Caps
6
‘Defensive’ Pharmaceutical Wholesalers In Focus

Jul 18 2024 - Australia
7
Twists And Turns Of Telix And Australian Biotech

Jul 10 2024 - Small Caps
8
Dr Boreham’s Crucible: Radiopharm Theranostics

Jul 03 2024 - Small Caps
9
Dr Boreham’s Crucible: Island Therapeutics

Jun 17 2024 - Small Caps
10
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps